NGeneBio엔젠바이오
354200 · KOSDAQ · ₩354200 · 엔젠바이오
- Market cap
- ₩11B
- Enterprise value
- ₩43B
- P/E
- —
- P/B
- 0.6×
- Dividend yield
- 0.0%
- ROE
- −26.3%
- Net margin
- −12.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−91.2% from the high
₩633Today: ₩652 – ₩771₩8,066
Returns
- 1W−28.7%
- 1M−44.1%
- 3M−67.7%
- 6M−85.2%
- YTD−83.3%
- 1Y−84.0%
- Volume today
- 478,452
- 0.3× the 20-day average
- Traded today
- ₩350M
- Listed shares
- 16,086,583
- EPS (12 months)
- −₩313
- Earnings yield −44.0%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumWeak-48.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
NGeneBio stock overview
NGeneBio (엔젠바이오, KRX: 354200) is listed on KOSDAQ, in the Business services sector. The company develops and supplies precision diagnostic products and solutions in precision medicine, built on next-generation sequencing (NGS) technology and genomic analysis software, and is expanding AI-based analysis using genomic and clinical data. Its shares closed at ₩712 on Oct 26, 2026, up 1.71% on the day, giving it a market value of ₩11B.
Key facts
- Market cap
- ₩11B
- Sector
- Business services
- Latest price change
- +1.71%
- As of
- Oct 26, 2026
- Main business
- The company develops and supplies precision diagnostic products and solutions in precision medicine, built on next-generation sequencing (NGS) technology and genomic analysis software, and is expanding AI-based analysis using genomic and clinical data.
Quick answers about NGeneBio
- What does NGeneBio do?
- The company develops and supplies precision diagnostic products and solutions in precision medicine, built on next-generation sequencing (NGS) technology and genomic analysis software, and is expanding AI-based analysis using genomic and clinical data. Its precision diagnostic business supplies gene panels and genomic analysis software for breast, blood and solid cancers to major hospitals in Korea, with some products sold in several overseas countries, and it also operates a drug and health supplement distribution business through subsidiaries.
- What is the market cap of NGeneBio?
- The market capitalisation of NGeneBio was ₩11B at the close on Oct 26, 2026.
- Who are the largest shareholders of NGeneBio?
- According to the latest official filings, the largest reported holders are SH Healthcare Investment No. 1 Fund (29.66%, as of Sep 17, 2026); Sangsangin Savings Bank (24.71%, as of Oct 30, 2025); Baro Savings Bank (20.50%, as of Oct 27, 2025).
- When is the next earnings report from NGeneBio?
- Korean companies rarely announce results dates in advance. Based on when NGeneBio filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 21, 2026.
Company profile
The company develops and supplies precision diagnostic products and solutions in precision medicine, built on next-generation sequencing (NGS) technology and genomic analysis software, and is expanding AI-based analysis using genomic and clinical data. Its precision diagnostic business supplies gene panels and genomic analysis software for breast, blood and solid cancers to major hospitals in Korea, with some products sold in several overseas countries, and it also operates a drug and health supplement distribution business through subsidiaries.
Written by AI from the company's latest annual report.
- Korean name
- 엔젠바이오
- Sector
- Business services
- Themes
- Biotech (new drugs)
- CEO
- 이경남
- Founded
- Oct 2015
- Listed
- Dec 2020
- Listed shares
- 16,086,583
- Fiscal year ends
- Month 12
- Website
- ngenebio.com
Similar companies
- S-1012750 · ₩3.5T₩93,300−2.81%
- Cheil Worldwide030000 · ₩2.2T₩19,170−1.13%
- Doosan Tesna131970 · ₩1.8T₩95,400−5.92%
- Lotte Tour Development032350 · ₩805B₩10,100−5.96%
- Soulbrain Holdings036830 · ₩737B₩35,950−3.36%
- Innocean Worldwide214320 · ₩691B₩17,270−1.99%
- Korea Ratings034950 · ₩458B₩100,800−0.20%
- GC005250 · ₩427B₩9,090−2.57%
Recent filings
See all- 5%+ holding reportOct 8, 2026
- Other Market NoticeOct 7, 2026
- Other Market Notice (Potential Designation as Administrative Issue – Market Capitalization Below ₩20B)Sep 22, 2026
- [Amended] Results of Securities Issuance (Voluntary Disclosure)Sep 22, 2026
- [Amended] Securities Issuance Performance ReportSep 22, 2026
Titles in Korean until English translations are added.
Also known as: NGeneBio / 엔젠바이오 / 354200 / KRX:354200
Source: KRX statistical information